Exploring Breakthroughs: Insights into Mitochondrial Disease Treatments and Clinical Trials | Ellen Wittmack Donnelly, CEO, Abliva AB. 00:10:00
This interview delves into the pioneering work of a biotech company focused on developing treatments for primary mitochondrial diseases, particularly highlighting their lead candidate undergoing a potentially pivotal Phase 2 study, offering insights into the drug's mechanisms and patient recruitment efforts, while outlining the company's vision for the future and its engagement in critical biotech meetings.
